Pediatric ALL treatment protocols in AYA patients: A retrospective study

Results from a retrospective study evaluating the implementation and healthcare utilization patterns of pediatric-inspired protocols for acute lymphoblastic leukemia (ALL) in 222 adolescent and young adult (AYA) patients aged 15–39 years treated within the Kaiser Permanente integrated healthcare system in California were published in Cancer Medicine by Newman et al. The study compared healthcare utilization patterns for patients treated with both pediatric (n = 148) and adult (n = 74) induction protocols, as well as therapeutic toxicities, complications, and mortality associated with each treatment approach.

Key data: Pediatric protocol use increased over the 8-year study period, approaching 90%. Pediatric protocols were associated with more outpatient clinic visits (mean, 48.5 vs 40.4 at 6 months; p = 0.0390) and fewer inpatient days (mean, 41.6 vs 65.1 at 6 months; p < 0.001) relative to adult protocols. No statistically significant differences in therapeutic complications were observed between treatment groups, with similar rates of bacteremia, mucositis, pancreatitis, peripheral neuropathy, sepsis, and liver injury. Crude mortality rates at any time were similar for pediatric vs adult protocols (23.7% vs 35.1%; p = 0.0994); 2-year mortality favored pediatric protocols (13.1% vs 27.4%; p = 0.0159).

Key learning: Pediatric protocols were associated with more outpatient clinical visits, fewer inpatient days, comparable toxicity profiles, and favorable mortality rates relative to adult protocols, supporting the adoption of pediatric protocols for AYA patients undergoing treatment for ALL in the community setting.